TB-500 QUESTIONS AND STUDY ANSWERS
TB-500: What the Short Answers Leave Out
Each answer names the test subject and substance. This helps you stop an animal result from becoming a human promise.
What TB-500 is in plain words
Human studies have not produced an approved treatment using TB-500 [13]. In the lab, the substance is a short chain that copies positions 17 through 23 of thymosin beta-4 [1]. Its chemical name won't help you weigh a health claim [1].
Where the name TB-500 comes from
The "TB" is short for thymosin beta. TB-500 is the research name for one short segment of thymosin beta-4 [1]. Another name has appeared in sales for animal use. Neither name tells you that this is the full protein, though many claims come from that protein.
What TB-500 changes inside a cell
Thymosin beta-4 holds one free part of actin in a 1:1 match, so one part holds one part [1][2]. Actin gives your cells shape and helps them move. X-rays showed the protein covering both ends of actin, which stopped a longer strand from forming [1]. People still lack proof that the short chain repairs tissue [10].
How TB-500 differs from thymosin beta-4
Positions 17 through 23 form the 7-amino-acid chain called TB-500 [1][5]. Full thymosin beta-4 has forty-three linked parts. On the dalton scale for tiny molecules, the full protein weighs about 4963 daltons and the short chain about 889 daltons [5]. The lower figure shows the short chain is much smaller; FDA also calls it part of thymosin beta-4 [13].
What makes up the TB-500 amino acid sequence
Seven amino acids, the small units in a protein, form the chain. The chain weighs about 889 daltons, on a scale made for very small molecules. This part of thymosin beta-4 can hold actin [1]. The chain starts with an acetyl group, a tiny chemical tag that names its form but doesn't show whether it works.
What TB-500 leaves out from thymosin beta-4
Chemists weigh tiny molecules in daltons; the TB-500 chain weighs about 889 daltons and full thymosin beta-4 about 4963 daltons [1][5]. The figures only show that the short chain is smaller. The short chain leaves out other parts of the full protein [5][10]. The full protein reached a Phase 1 human safety study, but the short chain did not [10].
What researchers try to learn from TB-500
Animal studies and dish tests looked at wounds, scars, hearts, stroke, and new blood vessels [5]. Most tested thymosin beta-4. The short chain hasn't proved a human benefit [10]. TB-500 interests researchers because it holds actin and may alter cell movement [1], but that doesn't prove healing in you.
What TB-500 studies say about torn muscle
In lab injury work, young muscle cells moved toward thymosin beta-4. In one mouse study, fresh muscle fibers formed, yet strength did not rise. Human recovery research hasn't put the short chain against a comparison treatment [10]. The muscle claim runs ahead of proof you can use.
Why cancer risk is still unknown for TB-500
High thymosin beta-4 levels have been found in several cancers. In lab work, the protein was tied to spreading cancer and feeding a tumor with new blood vessels [5]. Those same jobs may aid a wound. The concern is fair, but no study gives you a rate for the risk.
What the WADA ban means for TB-500
WADA, the world sports-doping regulator, bans TB-500 and thymosin beta-4 in its groups for growth and tissue repair [16]. Lab tests can find both substances in samples from people and horses. The ban can apply both in and out of a contest. For a tested athlete, the answer isn't hazy.
Why TB-500 isn't FDA approved
TB-500 isn't FDA approved for any treatment [13]. FDA once put TB-500, the short part of thymosin beta-4, in Category 2, used when FDA had a serious safety concern. The agency warned that the body might react, depending on how the substance entered it, and major safety facts were missing [13]. See TB-500 legal status and pharmacy rules for the current listing.
What human trials tested instead of TB-500
A completed human comparison trial for TB-500 does not exist [10]. Human studies gave full thymosin beta-4 through a vein in Phase 1 and used dry-eye drops called RGN-259 [10]. The vein study looked for harm and tracked the protein through the body. An early shot trial of thymosin beta-4 was withdrawn before it began, so it produced no results.
What TB-500 can't tell you about timing
No one knows a human healing timetable for the short chain [10]. In a rat wound study, full thymosin beta-4 raised new skin coverage 42% by day four and up to 61% by day seven [7]. Those days belong to rats given the full protein. They don't give the seven-part chain a human schedule.
What TB-500 studies found in ligaments
One rat study found better healing in a medial collateral knee ligament after thymosin beta-4 [5][10]. That result helps explain the sports interest. People haven't been tested with a comparison group. The intact protein gave the ligament result, so the short chain can't answer what happens to your tendon or ligament.
What TB-500 heart studies found
In rodents, thymosin beta-4 helped more heart cells live when researchers closed a heart artery [6]. The animals' hearts then worked better. Yet a pig study of full thymosin beta-4 did not find less heart damage. The animal findings conflict, and neither test answers the human question for the short chain.
What blood-vessel growth means for TB-500
Thymosin beta-4 helps cells from the lining of blood vessels move [5]. It also helps new vessels grow. A wound may use that blood supply, but a tumor may use it too. The same effect sits under both a repair claim and a safety concern.
What TB-500 stroke studies found
Researchers gave full thymosin beta-4 after strokes in rats. The animals moved better at 2 and 12 milligrams per kilogram of body weight. Rats at 18 milligrams per kilogram did not improve [8]. Human stroke work hasn't tested the short chain [10], so the rat result only shows that more wasn't better in rats.
What TB-500 hair studies found
Very small lab amounts of thymosin beta-4 woke up stem cells near hair roots [5]. Rats and mice then grew hair faster. The whole protein went to those animals. The result did not show that TB-500 grows hair on a person.
What TB-500 studies found about swelling
In a dish, cells released less IL-8, a substance that helps drive swelling [12]. The test used thymosin beta-4. These aren't human results for the short chain. They don't predict how your sore joint will feel.
What isn't known about TB-500 side effects
Researchers haven't compared the short chain with inactive treatment in people [10]. The main theory involves new blood vessels feeding a tumor [5]. The vial could contain a different chain or unwanted material. Safety for the seven-part chain in people is unknown, not reassuring.
Why TB-500 and BPC-157 aren't the same
The two are different research peptides. TB-500 carries the actin-holding part of thymosin beta-4 [1]. A 2026 review found too little human safety work for both [11]. Neither is approved for human use, and researchers haven't compared the pair in people, so a combined claim has no sound proof.
What TB-500 wound studies really tested
Full thymosin beta-4 helped animal wounds close, cover with new skin, and lay down collagen [7][3]. A lab-made actin-holding chain also helped wounds in mice. The seven-part result is still animal work. The short chain has no proved human wound result [10].
Where TB-500 stands under the law
FDA's page, current to April 22, 2026, lists the TB-500 request as withdrawn. That means the requester pulled it back; it doesn't mean approval or clear pharmacy access. The substance no longer appears in Category 2, FDA's group for substances with a serious safety concern [13].
WADA bans it in tested sport [16]. This is general legal information, not legal advice. The TB-500 legal status and pharmacy rules page explains the open pharmacy question.
Whether a pharmacy may compound TB-500
FDA hasn't told pharmacies whether they may make TB-500 to order. FDA put the substance in Category 2 because it saw a serious safety concern [13]. The request was later withdrawn, and that concern still sits on FDA's page. A raw ingredient must also meet the federal rule for that kind of pharmacy [15].
A pharmacy-made drug needs a licensed prescriber and one patient's valid prescription [15]. That step is needed, but it isn't enough. A prescription can't make a disallowed raw material lawful.
What the current FDA listing says about TB-500
On September 29, 2023, FDA put TB-500, the short part of thymosin beta-4, in Category 2 [13]. Category 2 meant FDA might act against pharmacies that used the substance [13]. The current page says the request was withdrawn. That change is not FDA approval.
The July 23–24, 2026 meeting agenda listed TB-500 too [14]. Outside advisers talked through its use as a pharmacy ingredient there. FDA has shared no record of their votes, and the meeting doesn't change what you may do.